BRAIN Biotech

Industry

Cosmetics, Feed, Industrial chemistry

Topics

Enzymes & biocatalysis, Animal feed & feed additives, Hyaluronic acid, collagen & cosmetic bio-actives

Role

Producer — “…signed to move products and processes forward with innovative biosolutions. They position themselves as a part…”

Why it is bioeconomy

BRAIN Biotech is an industrial biotechnology company specializing in the development, production, and distribution of specialty enzymes, microbial production strains, and bio-based solutions for the food, life sciences, and environmental sectors.

Not yet cited as a supplier in a graded solution.

Subsidiaries: BRAIN UK II Ltd. · Biocatalysts Ltd. · Biocatalysts Inc. · WeissBioTech GmbH · Breatec B.V. · RMH AG · AnalytiCon Discovery LLC · Biosun Biochemicals Inc.

• 2026-10 Latest status: Dr. Sven K. Weber is appointed as the new Chairman of the Executive Board (CEO), effective October 1, 2026, succeeding Adriaan Moelker. ↗ ↗ ↗

Recent news 5

Found by automated search; summaries are machine-written in English. The headline names the company or the summary is about it — check the source before relying on it.

• 2026-09-09 BRAIN Biotech AG Receives EUR 11.51 Million Major Milestone Payment from Royalty Pharma | Ad-hoc - EQS News eqs-news.com
  BRAIN Biotech AG has received an additional EUR 11.51 million milestone payment from Royalty Pharma for progress on the investigational compound deucrictibant, boosting expected future payments up to EUR 96.65 million. The deal also triggers a one-time non-cash IFRS 9 charge (up …
• 2026-09-09 BRAIN Biotech AG Receives EUR 11.51 Million Major Milestone Payment from Royalty Pharma | Ad-hoc - EQS News eqs-news.com
  BRAIN Biotech AG reports a new EUR 11.51 million milestone payment from Royalty Pharma tied to progress of the investigational drug deucrictibant, boosting expectations for further up to EUR 96.65 million in future milestones. It also notes a one-time non-cash IFRS 9 charge up to …
• 2026-07-29 Dr. Sven K. Weber Succeeds Adriaan Moelker as CEO of BRAIN Biotech AG | Corporate - EQS News eqs-news.com
  Dr. Brain Biotech AG will appoint Dr. Sven K. Weber as CEO (effective Oct 1, 2026), with current CEO Adriaan Moelker retiring by Jan 2027 but staying as a senior advisor until then; the company emphasizes continued growth in specialty enzymes, expansion via the BRAINBioIncubator, …
• 2026-07-13 BRAIN Biotech AG signs new Revolving Credit Facility with MP Beteiligungs-GmbH | Ad-hoc - EQS News eqs-news.com
  BRAIN Biotech AG has arranged a new €9.0 million revolving credit facility with MP Beteiligungs-GmbH, maturing December 31, 2028, with interest at 6-month Euribor plus 233 basis points, intended for general corporate financing and debt servicing.
• 2026-05-28 BRAIN Biotech AG reports half-year figures for fiscal year 2025/26 and confirms full year guidance | BRAIN Biotech Group brain-biotech-group.com
  BRAIN Biotech reports first-half 2025/26 revenue of €23.4m (down 7.2% YoY) with adjusted EBITDA near break-even (-€0.1m) and notes production relocations affecting Biocatalysts sales, while highlighting strong progress in its BRAINBioIncubator with a granted CRISPR nuclease …

Ownership & investors 8

Partners & deals 1

Similar companies

Biocatalysts Ltd · c-LEcta GmbH · Biocatalysts Baking · Leaf by Lesaffre · Biocatalysts Beverages · BiCT srl - Biological and Chemical Technologies · Bio Base Europe Pilot Plant · Global BioTech S.L